Frovatriptan je organsko jedinjenje, koje sadrži 14 atoma ugljenika i ima molekulsku masu od 243,304 Da.[1][2][3][4][5][6][7][8]

Frovatriptan
Klinički podaci
Prodajno imeFrova, Frovelan, Miguard
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije26 h
IzlučivanjeRenalno
Identifikatori
CAS broj158747-02-5 ДаY
ATC kodN02CC07 (WHO)
PubChemCID 77992
DrugBankDB00998 ДаY
ChemSpider70378 ДаY
ChEMBLCHEMBL1279 ДаY
Hemijski podaci
FormulaC14H17N3O
Molarna masa243,304
  • CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O
  • InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 ДаY
  • Key:XPSQPHWEGNHMSK-SECBINFHSA-N ДаY
Osobina Vrednost
Broj akceptora vodonika 2
Broj donora vodonika 3
Broj rotacionih veza 2
Particioni koeficijent[9] (ALogP) 1,4
Rastvorljivost[10] (logS, log(mol/L)) -3,6
Polarna površina[11] (PSA, Å2) 70,9

Reference

уреди
  1. ^ Markus F, Mikko K: Frovatriptan review. Expert Opin Pharmacother. 2007 Dec;8(17):3029-33. PMID 18001261
  2. ^ Easthope SE, Goa KL: Frovatriptan. CNS Drugs. 2001;15(12):969-76; discussion 977-8. PMID 11735616
  3. ^ Balbisi EA: Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Sep;2(3):303-8. PMID 18360605
  4. ^ Balbisi EA: Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract. 2004 Jul;58(7):695-705. PMID 15311727
  5. ^ Elkind AH, Wade A, Ishkanian G: Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol. 2004 Oct;44(10):1158-65. PMID 15342617
  6. ^ Jhee SS, Shiovitz T, Crawford AW, Cutler NR: Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. PMID 11327198
  7. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  8. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.  уреди
  9. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  10. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди
  11. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

Literatura

уреди

Spoljašnje veze

уреди


 Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).